Results 141 to 150 of about 11,456 (188)

Neuropsychiatric adverse events of SGLT2 inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system database. [PDF]

Front Med (Lausanne)
Yin M, Tan H, Xie S, Kuang Y, Wu Q, Ma J, Guo C.   +6 more
europepmc   +1 more source

The SGLT2i "canagliflozin" and the DPP-4i "sitagliptin" mitigate hypertensive nephropathy in adult male rats by modulating the Ang II/RAGE/Nox4/NLRP3 cascade. [PDF]

Front Physiol
Hassan FE, Al-Shahed FAN, Selmy A, Mahmoud LM, Aldreny BA.   +4 more
europepmc   +1 more source

SGLT2 Inhibitors Promote Diabetic Wound Healing Via AMPK/AKT/mTORC1-Regulated Endothelial Angiogenesis. [PDF]

Arterioscler Thromb Vasc Biol
Bestepe F, Ghanem GF, Kelly C, Huseynli K, Richards DV, Barber R, Zamary A, Sahu P, Salehi P, Huggins GS, Icli B.   +10 more
europepmc   +1 more source

From molecules to the clinic-pathophysiology of sodium-glucose cotransporter 2 inhibitors and their emerging role in urology: A comprehensive review from the European Association of Urology Section of Endourology. [PDF]

Asian J Urol
Talyshinskii A, Gauhar V, Kar Kei Yuen S, Güven S, Tokas T, Tsaturyan A, Enikeev D, Somani B.   +7 more
europepmc   +1 more source

The impact of SGLT2 inhibitors on uric acid levels in patients with heart failure with preserved ejection fraction: integration of mechanisms and clinical evidence. [PDF]

Front Cardiovasc Med
Zhang Y, Xiao X, Yan Q, Huang D, Wang W.
europepmc   +1 more source

Beneficial Effects of Canagliflozin in Heart Failure Associated With Cardiac and Surgical Procedures. [PDF]

Rev Cardiovasc Med
Dong Y, Zhou F, Chi L, Mu J.
europepmc   +1 more source

Acarbose or Canagliflozin vs. Placebo to Ameliorate Post-Bariatric Hypoglycaemia: The Clinical Outcomes of the HypoBar I Randomised Clinical Trial. [PDF]

Diabetes Obes Metab
Lobato CB, Winding CT, Bojsen-Møller KN, Hartmann B, Martinussen C, Veedfald S, Holst JJ, Madsbad S, Jørgensen NB, Dirksen C.   +9 more
europepmc   +1 more source

Metabolic Concepts of Sodium-Glucose Cotransporter 2 Inhibitors-Based Therapies Against Hepatocarcinogenesis and Therapy Resistance in Hepatocellular Carcinoma. [PDF]

Life (Basel)
Chung HH.
europepmc   +1 more source

Comparative clinical outcomes and safety of finerenone, SGLT2 inhibitors, RAS inhibitors and ARNI in heart failure with preserved or mildly reduced ejection fraction: a systematic review and network meta-analysis. [PDF]

Front Pharmacol
Fu Z, Chen X, Liu H, Yang J, Jin T, Liu T, Ta G.   +6 more
europepmc   +1 more source

Efficacy and safety of novel antidiabetic drugs in patients with type 2 diabetes and chronic kidney disease: a network meta-analysis. [PDF]

Front Endocrinol (Lausanne)
Zhu X, Wang X, Zhang P, Yang Z, Zhao N, Li J, Shi Y, Zhao Y, Ma J.   +8 more
europepmc   +1 more source